Search results for "Hemorrhagic disorder"

showing 3 items of 3 documents

Pathogen safety of long-term treatments for bleeding disorders: still relevant to current practice

2013

Hemophilia defines a group of hereditary bleeding disorders: hemophilia A (deficiency of Factor VIII, FVIII), hemophilia B (deficiency of FIX), and para-hemophilia (deficiency of FV). These result from mutations in clotting factor genes. As in the large majority of bleeding disorders ([Table 1][1

congenital hereditary and neonatal diseases and abnormalitiesPediatricsmedicine.medical_specialtyTime FactorsLong term treatmentBlood transfusionmedicine.medical_treatmentTreatment outcomeEditorials and PerspectivesHemophilia AHemorrhagic DisordersHemorrhagic disorderhemic and lymphatic diseasesBlood-Borne PathogensmedicineHumansBlood TransfusionPathogenClotting factorbusiness.industryHematologyRecombinant ProteinsTreatment OutcomeCurrent practiceImmunologybusiness
researchProduct

Management of Kidney Transplantation in a Factor VII-Deficient Patient: Case Report

2012

Transplantation in patients with congenital bleeding disorders is a challenge requiring an integrated approach of various specialists. Renal transplantation, the most frequent type of solid organ transplantation, is rarely performed in individuals with congenital hemorrhagic disorders. We performed a renal transplantation in a 53-year-old man with end-stage renal disease and congenital coagulation factor VII deficiency, a rare bleeding disorder with a peculiar clinical picture requiring replacement therapy in surgical interventions. Perioperative bleeding was successfully prevented by administration of recombinant activated factor VII. Treatment schedule, administration rate, and long-term …

Malemedicine.medical_specialtyDiseaseHemorrhagic disorderchemistry.chemical_compoundHumansMedicinekidney transplatation congenital bleeding disorders factor VII deficiency recombinant factor VII major surgerykidney transplantation inherited coagulation disorderCoagulation factor VIIKidney transplantationTransplantationFactor VIIbusiness.industryPerioperativeMiddle Agedmedicine.diseaseKidney TransplantationSurgeryTransplantationchemistryTreatment ScheduleFeasibility StudiesKidney Failure ChronicSurgerybusiness
researchProduct

Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet

2019

Abstract Since the comprehensive recommendations for the management of acute promyelocytic leukemia (APL) reported in 2009, several studies have provided important insights, particularly regarding the role of arsenic trioxide (ATO) in frontline therapy. Ten years later, a European LeukemiaNet expert panel has reviewed the recent advances in the management of APL in both frontline and relapse settings in order to develop updated evidence- and expert opinion–based recommendations on the management of this disease. Together with providing current indications on genetic diagnosis, modern risk-adapted frontline therapy, and salvage treatment, the review contains specific recommendations for the …

Acute promyelocytic leukemiamedicine.medical_specialtymedicine.medical_treatmentImmunologyMEDLINETretinoinDiseaseHemorrhagic DisordersBiochemistryHemorrhagic disorderEuropean LeukemiaNetArsenic TrioxideLeukemia Promyelocytic AcutePregnancyRecurrenceHumansMedicineDisease management (health)Intensive care medicineSpecial ReportNeoadjuvant therapyAPL Differentiation SyndromeAgedbusiness.industryDisease ManagementCell BiologyHematologymedicine.diseasePractice Guidelines as TopicFemalebusinessBlood
researchProduct